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Background: Patients with chronic obstructive pulmonary disease (COPD) can be categorized as having frequent
(FE) or infrequent (IE) exacerbations depending on whether they respectively experience two or more, or one or
zero exacerbations per year. Although most patients do not change category from year to year, some will, and the
factors associated with this behaviour have not been examined.
Methods: 1832 patients completing two year follow-up in the Evaluation of COPD Longitudinally to Identify
Predictive Surrogate End-points (ECLIPSE) study were examined at baseline and then yearly. Exacerbations were
defined by health care utilisation. Patient characteristics compared between those patients who did or did not
change exacerbation category from year 1 to year 2.
Findings: Between years 1 and 2, 221 patients (17%) changed from IE to FE and 210 patients (39%) from FE to IE.
More severe disease was associated with changing from IE to FE and less severe disease from FE to IE. Over the
preceding year, small falls in FEV1 and 6-minute walking distance were associated with changing from IE to FE, and
small falls in platelet count associated with changing from FE to IE.
Conclusion: No parameter clearly predicts an imminent change in exacerbation frequency category.
Trial registration: SCO104960, clinicaltrials.gov identifier NCT00292552
Keywords: COPD, Exacerbations, Exacerbation frequency, Exacerbation phenotypeBackground
The natural history of chronic obstructive pulmonary
disease (COPD) is punctuated by exacerbations defined
as episodes of acute symptomatic deterioration that may
warrant a change in treatment [1,2]. Frequent exacerba-
tions are associated with reduced quality of life [3],
increased airway inflammation [4], accelerated lung func
tion decline [5] and increase mortality [6]. Patients with
frequent exacerbations make more visits to their medical
practitioner, require more medication, experience more
hospital admissions [7] and consequently impose a
greater financial burden on health services [8,9].
The number of exacerbations a patient experiences
over a year is very strongly associated with their fre-
quency in the previous year [3,7]. This stability in* Correspondence: g.donaldson@ucl.ac.uk
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distribution, and reproduction in any mediumexacerbation frequency means that patient recall of
events in the previous year can be used to categorize
patients as having frequent (FE) or infrequent (IE) exa-
cerbations during the subsequent year [7,10]. These cat-
egories are now recognised as important COPD patient
phenotypes that influence the clinical management of
the patient [11]. Although exacerbation frequency is
relatively stable in most patients, some year on year vari-
ation exists and the factors associated with any change
in category have not yet been investigated. Therefore we
analysed the data from the “Evaluation of COPD lon-
gitudinally to identify predictive surrogate endpoints
(ECLIPSE)” study to determine whether patients kept or
changed their IE or FE category. Previously, three groups
of 0, 1 and 2+ exacerbations per a year have been de-
scribed [7] but interpretation of the nine potential tran-
sitions would be complex and less clinically relevant. In
this study, we have also examined a slightly smaller
group of 1832 patients who completed two years oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Timing of assessment and patient exacerbation
categorization during the initial two years of the ECLIPSE study.
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rolled into the ECLIPSE study [7] since the exacerbation
frequency measured over both years 1 and 2 was needed
to identify patients who did or did not changed IE and
FE categories.
Additionally we tried to establish whether specific fac-
tors were associated with a change in exacerbation fre-
quency as such data would be useful in identifying
patients with an increased risk of a worsening exacerba-
tion frequency and potentially suggest ways to prevent
this clinically important change. Some of the results of
this study have been previously reported in the form of
an abstract [12].
Methods
Study design and patients
All patients provided written informed consent and the
study was approved by the relevant ethics and review
boards ([13]; see online supplement). Eligible patients
were aged between 40 and 75 years, with a 10 or more
pack-year smoking history, a post-bronchodilator forced
expiratory volume in 1 second (FEV1) of less than 80%
predicted from age, height and sex [14] and a ratio of
FEV1 to forced vital capacity (FVC) of 0.7 or less.
All patients completing at least 2 years of observation
are included in this study. Patients underwent compre-
hensive medical reviews at baseline and then at the end
of each 12 months of observation (see Figure 1). Data
recorded at the 3, 6 and 18 month visits have not been
analysed in this study as data on some patient charac-
teristics were not available at these time points. Patients
underwent standard spirometry testing after the admin-
istration of 400 μg of inhaled albuterol, completed a
modified Medical Research Council dyspnoea scale
(mMRC) and a St. Georges Respiratory Questionnaire
(SGRQ). Co-morbidities were assessed from questions in
the American Thoracic Society–Division of Lung Dis-
eases (ATS-DLD) questionnaire and symptoms of de-
pression by the Center for Epidemiologic Studies of
Depression (CES-D) questionnaire. A venous blood sam-
ple was taken and a medical history including start/stop
dates of medications and smoking history recorded. The
patients underwent a six minute walking test (6MWD)
according to ATS guidelines [15], with distance expressed
as a percentage of predicted [16] which was used in calcu-
lating the patient’s BODE index [17]. Patients also under-
went computed tomographic (CT) scanning, at baseline
and year 1, to evaluate the severity of emphysema as the
percentage of low attenuation areas (LAA%) [18].
Blood samples were dispatched immediately after each
visit for a full-blood count, and serum and plasma
samples stored at −80°C until assayed for fibrinogen,
creactive protein (CRP), surfactant protein D (SP-D) and
pulmonary activation regulated chemokine (PARC) [19].Any samples with values below the lower limit of quanti-
fication were assigned a value that was half of the assay
lower limit.
Exacerbations were defined by health care utilization
requiring the prescription of antibiotics and/or oral cor-
ticosteroids by the patient’s primary care clinician or
study personnel, or hospitalisation for an exacerbation.
To ensure capture of these events patients were asked at
clinic visits and during monthly telephone calls about
visits to health care professionals and change in medica-
tions. The end of an exacerbation was based on investi-
gator judgement, and no new exacerbation could start
before resolution of an existing exacerbation. Frequent
exacerbations were defined as 2 or more per year, and
infrequent exacerbations as 1 or zero per year.
Statistical analysis
Patients were categorized according to their exacerba-
tion frequency assessed over year 1 of follow-up; whe-
ther they changed category was assessed using year 2 of
follow-up. No data on how many exacerbations the pa-
tient recalled experiencing in year prior to recruitment
was used in this analysis. Cross-sectional patient cha-
racteristics obtained at the year 1 assessment were ex-
amined in relation to those who did or did not change
category, rather than the baseline assessment, as this
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“Longitudinal” characteristics were calculated as the dif-
ference between baseline and the year 1 assessment -
that is, over the year preceding the point of change in
exacerbation frequency (see Figure 1).
Means and standard deviations are reported for the
continuous variables, with frequencies reported for the
categorical variables. For tests between exacerbation fre-
quency groups, an analysis of variance (ANOVA) for
continuous variables or chi-square test for categorical
variables was used. Due to skewed distributions, blood
and plasma biomarkers were summarized using medians
and inter-quartile ranges (IQR). Comparisons of their
distributions across exacerbation frequency groups used
a Kruskal-Wallis test.Results
Change in exacerbation category
1832 patients completed at least 2 years of follow-up
and had data available for this analysis.
543 of the 1832 patients (30%) had frequent exa-
cerbations and 1289 (70%) infrequent exacerbations at
the end of year 1 of follow-up. Between years 1 and 2,
431 of the 1832 patients (24%) changed category, 221
(17%) of the IE patients changed category to FE com-
pared to 210 (39%) of the FE patients who changed to
IE (P<0.001).
Table 1 shows the demographic characteristics of all
1832 patients recorded at the year 1 assessment, and
after division into infrequent (IE) and frequent exacer-
bator (FE) groups by their observed exacerbation fre-
quency over year 1.Change in exacerbation frequency
Figure 2A shows a histogram for the change in exacerba-
tion frequency between years 1 and 2 of the 1832 patients.
44% of the patients had an identical exacerbation fre-
quency in years 1 and 2, and for those patients whose ex-
acerbation frequency did change, the magnitude and
direct of the changes were evenly distributed around zero.
This was consistent with the finding that the number of
exacerbations per patient per year (PPPY) was 1.17 in both
year 1 and year 2. However, when sub-divided into IE and
FE groups, exacerbation frequency was seen to increased
from 0.35 PPPY in year 1 to 0.70 PPPY in year 2, while in
the FE group, it fell from 3.10 PPPY in year 1 to 2.30 PPPY
in year 2. Figures 2B and 2C show that the distribution of
these changes was not symmetrical. In the IE group, the
distribution was skewed because exacerbation frequency
could not fall by more than 1 exacerbation per year. In the
FE group, without such restriction, there was a more even
distribution but still many more patients in the −1 and −2
category than in the +1 or +2 category.Patient characteristics associated with IE to FE, and FE to
IE category changes
Table 2 shows the cross-sectional characteristics of
patients at the year 1 assessment, divided into those
who did or did not change exacerbation category be-
tween years 1 and 2. Patients who changed from IE to
FE had worse, and those changing from FE to IE better
baseline post-bronchodilator FEV1, FEV1% predicted,
mMRC, SGRQ-C, BODE, anxiety and hospitalised exa-
cerbations per patient per year than those who re-
mained in the respective categories. However, some
patient characteristics were unique to the direction of
change. Patients changing from IE to FE were more
likely to be female, have a lower BMI, poorer FEV1/
FVC ratio, less diabetes, more symptoms of depression
and more emphysema (LAA%), but these factors were
not different in those who remained FE compared to
those who changed from FE to IE. Similarly, for the FE
to IE transition, a greater 6MWD and lower systemic
inflammation (CRP, Fibrinogen, PARC) were significant
factors not seen in IE patients changing to FE.
A total of 116 patients (6.4%) either started or stopped
any maintenance treatment for COPD, i.e. LAMA,
LABA, ICS and ICS/LABA combination between base-
line and year 1 of follow-up; ninety-five patients (5.2%)
initiated maintenance treatment and 21 (1.2%) stopped
maintenance treatment.
Change in patients characteristics over year 1
Table 3 shows the “longitudinal” changes in patient char-
acteristics from baseline to the Year 1 assessment that
took place before the category transitions. Falls in plate-
let count were significantly associated with a future
category change from FE to IE whereas; falls in FEV1
and in 6MWD were significantly associated with chan-
ging from IE to FE. Table 3 also reports differences in
the number of exacerbations either hospitalised and/or
treated with oral corticosteroids. These two charac-
teristics were assessed over the same time periods as the
exacerbation categories and cannot therefore be consi-
dered as prospective markers. The patients who changed
from IE in year 1 to FE in year 2 had 0.57 hospitalized
exacerbation per patient year compared to 0.07 per pa-
tient year in IE patients who did not change category.
Similarly, there were only 0.14 hospitalised exacerbations
per patient year in those changing from FE to IE com-
pared to 0.68 in those who remained FE. These results
were consistent with the data on oral corticosteroid
treated exacerbations.
Discussion
This study is the first to examine in a large dataset the
factors associated with changes in the exacerbation fre-
quency category of patients with COPD. We had hoped
Table 1 Patient characteristics at the year 1 assessment: data is presented for all patients and sub-divided by
exacerbation category in year 1 of follow-up
All COPD (n=1832) FE (n=543) IE (n=1289) p-value FE v IE
Age (years) 64 (7) 64 (7) 64 (7) 0.751
Females (%) 35% 41% 32% <0.001
BMI (kg/m2) 27 (6) 26 (6) 27 (6) 0.006
Active smoker (%) 36% 33% 37% 0.113
*FEV1 (L) 1.37 (0.55) 1.14 (0.45) 1.47 (0.55) <0.001
*FEV1 %predicted 49 (16) 43 (16) 52 (16) <0.001
*FEV1/FVC % 45 (12) 41 (12) 46 (12) <0.001
6-minute walk distance (m) 385 (123) 350 (119) 399 (122) <0.001
%predicted 6MWD 74 (24) 69 (23) 77 (23) <0.001
Blood oxygen saturation (%) 94.7 (2.9) 94.2 (3.1) 94.9 (2.8) <0.001
Emphysema LAA% (−950HU) 18 (12) 20 (13) 17 (12) <0.001
mMRC Dyspnoea Score 1.7 (1.1) 2.0 (1.1) 1.5 (1.0) <0.001
SGRQ-C Total Score 47 (21) 57 (18) 43 (21) <0.001
BODE Index 3.0 (2.1) 3.9 (2.2) 2.7 (2.0) <0.001
White blood cells (10^9/L) 7.6 (2.2) 8.1 (2.4) 7.4 (2.0) <0.001
Platelets (10^9/L) 266 (71) 276 (75) 261 (69) 0.002
Fibrinogen (mg/dL) 436 [383–504] 468 [405–535] 426 [376–492] <0.001
CRP (mg/dL) 3.3 [1.5-7.3] 4.1 [1.8-9.1] 3.1 [1.4-6.6] <0.001
SP-D (ng/mL) 119 [87–163] 115 [86–159] 121 [87–166] 0.294
PARC/CCL-18 (ng/mL) 112 [87–145] 119 [92–154] 111 [85–141] 0.001
Neutrophils (10^9/L) 5.0 (1.9) 5.4 (2.2) 4.8 (1.8) <0.001
Treated with ICSL % 71% 81% 66% 0.159
Treated with LAMA % 63% 68% 60% <0.001
Treated with ICS % 17% 15% 17% 0.336
Treated with LABA % 14% 14% 15% 0.813
Treated with Oxygen % 10% 16% 6% <0.001
PPPY COPD Hosp. Year 1 0.20 0.55 0.05 <0.001
PPPY OCS only exbs Y1 0.13 0.35 0.04 <0.001
Diabetes 10% 8% 10% 0.287
Cardiovascular (excl. HTN) 33% 32% 33% 0.868
Reflux/heartburn 26% 33% 23% <0.001
Anxiety 16% 21% 14% <0.001
Depression symptoms 25% 33% 21% <0.001
P-values are for comparisons between patients with Frequent (FE) and Infrequent exacerbations (IE). Mean (SD) or Median [25% - 75% percentile].
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physicians to an imminent change in category but no
single parameter emerged. Those variables that did
change in the year before IE patients became frequent
exacerbators (falls in FEV1 and 6-minute walking dis-
tance) or FE patients switched to IE (fall in platelet
count) were too small in magnitude relative to the over-
all variability to provide a useful predictive tool. We did
observe more hospitalized exacerbations in those chan-
ging from IE to FE, and fewer hospitalized exacerbationsin those changing from FE to IE, compared to those pa-
tients who remained in their category. Since, the number
of hospitalized exacerbation over year 1 partly deter-
mined how the patients were categorized; this parameter
could not be considered sufficiently independent or pro-
spective for predicting a change in category. However, it
is possible that the presence, or absence, of exacerba-
tions severe enough to warrant hospital admission indi-
cates a transition in the trajectory of the disease. Our
results highlight the multi-facetted nature of the disease
Figure 2 Distribution of exacerbation frequency change. All COPD patients (A) and in patients classified as IE (B) and FE (C) in year 1.
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the frequent exacerbator phenotype.
Across the whole study population, exacerbation fre-
quency was unchanged in year 2 compared to year 1.
This agrees with another observational study that found
no change in exacerbation frequency over 6 years of
follow-up albeit with a symptomatic definition of exacer-
bation [20]. Aaron and colleagues have reported with
transitional regression models that patients experience a
significant acceleration in the rate of exacerbations over
just one year [21]. It might be that changes in inter-
exacerbation intervals provide a more sensitive measure
of changes in exacerbation frequency over time, but this
metric lacks the simplicity required for clinical assess-
ment. We observed that 44% of patients had no change
in exacerbation frequency between years 1 and 2. In the
remaining 56% of patients, the changes in frequency had
a bell-shaped distribution with an approximately equal
number of rises and falls. This could simply be “reg-
ression to the mean” but there will also be some random
variability in the number of viruses and bacteria circulating
in the community which are thought to trigger the majority
of COPD exacerbations [22,23].
The rise in exacerbation frequency that we observed in the
IE group could involve four factors. Firstly, our definition of
IE as 0 or 1 exacerbation per a year meant that falls inexacerbation frequency were restricted to a maximum
of −1 per year, but there was no limit to any rise in fre-
quency, and the maximum increase we observed was +10
per year. Secondly, COPD progresses and higher exacerba-
tion frequencies are more likely to be reported in more se-
vere patients [24]. We found that the patients who
changed from IE to FE were generally more severe than
those who stayed in the IE group over a wide range of pa-
tient characteristics. Thirdly, some patient characteristics
fell over the year preceding the change from IE to FE. An
acute deterioration is occasionally observed in clinical
practice but the underlying reasons for the change are not
totally recognised. The physiological markers that wors-
ened relative to the normal reduction observed in those
patients who did not change category were FEV1 and
6MWD. These are important indicators of COPD severity,
with rapid decline in both FEV1 [25] and 6MWD [26] as-
sociated with increased mortality. Unfortunately, the mag-
nitude of the falls in FEV1 and 6MWD were small
compared to their overall variability and thus would not
make useful targets for monitoring risk or early interven-
tion. Fourthly, it is possible that exacerbation frequency
changed because patients started to seek treatment for
previously unreported exacerbations or increased their ad-
herence to already prescribed treatments. About 50% of
exacerbations in patients with moderate to severe COPD
Table 2 Patient characteristics at year 1 assessment split by exacerbation phenotype over study years 1 and 2
Year 1 Category Year 1 IE (n=1289) Year 1 FE (n=543)
Year 2 Category Stayed as IE
(n=1068)
Change to FE
(n=221)
p-value Stayed as FE
(n=333)
Change to IE
(n=210)
p-value
Characteristics at Year 1 Assessment
Age (years) 64 (7) 64 (7) 0.496 64 (7) 65 (7) 0.508
Females (%) 31% 41% 0.002 42% 40% 0.561
BMI (kg/m2) 27 (6) 26 (5) 0.007 26 (6) 26 (5) 0.918
Active smoker (%) 37% 35% 0.646 33% 32% 0.776
*FEV1 (L) 1.52 (0.56) 1.23 (0.45) <0.001 1.09 (0.41) 1.23 (0.50) <0.001
*FEV1 %predicted 53 (16) 45 (15) <0.001 41 (15) 46 (16) 0.001
*FEV1/FVC % 47 (12) 43 (11) <0.001 41 (11) 43 (12) 0.098
6-minute walk distance (m) 402 (124) 388 (114) 0.125 339 (125) 368 (107) 0.006
%predicted 6MWD 77 (23) 76 (22) 0.480 66 (24) 73 (21) 0.002
Blood oxygen saturation (%) 95.0 (2.8) 94.4 (2.7) 0.012 93.9 (3.2) 94.5 (2.7) 0.031
Emphysema LAA% (−950HU) 16 (12) 20 (13) <0.001 21 (13) 19 (13) 0.126
mMRC Dyspnoea Score 1.5 (1.0) 1.7 (1.1) 0.004 2.1 (1.0) 1.8 (1.1) <0.001
SGRQ Total Score 41 (18) 47 (19) <0.001 57 (16) 50 (16) <0.001
BODE Index 2.5 (1.9) 3.3 (2.0) <0.001 4.2 (2.2) 3.4 (2.2) <0.001
White blood cells (10^9/L) 7.4 (2.0) 7.5 (2.2) 0.926 8.2 (2.5) 7.9 (2.1) 0.082
Neutrophils, (10^9/L) 4.8 (1.7) 4.9 (2.1) 0.601 5.6 (2.4) 5.2 (1.9) 0.084
Platelets (10^9/L) 261 (70) 263 (69) 0.713 281 (77) 268 (70) 0.055
Fibrinogen (mg/dL) 423 [376–490] 438 [380–502] 0.092 480 [416–543] 444 [388–508] <0.001
CRP (mg/dL) 3.0 [1.4-6.5] 3.4 [1.6-7.6] 0.071 4.7 [2.1-10.4] 3.1 [1.6-6.9] 0.002
SP-D (ng/mL) 121 [86–167] 125 [89–162] 0.625 116 [85–162] 114 [88–157] 0.651
PARC/CCL-18 (ng/mL) 111 [86–141] 110 [83–141] 0.943 121 [94–162] 113 [87–145] 0.027
PPPY COPD Hosp. Year 1 0.04 0.12 <0.001 0.65 0.38 0.004
PPPY OCS only exbs Y1 0.04 0.05 0.218 0.38 0.29 0.218
Diabetes 11% 6% 0.024 8% 9% 0.689
Cardiovascular (excluding
HTN)
33% 33% 0.904 29% 37% 0.072
Reflux/heartburn 23% 23% 0.890 32% 33% 0.888
Anxiety 13% 20% 0.003 24% 16% 0.022
Depression symptoms 20% 29% 0.004 36% 28% 0.058
P-values are comparisons between those who stayed in or changed exacerbation category. Data are mean (SD) or median [25% - 75% percentile].
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similar to reported exacerbations in symptoms and spiro-
metric changes [27] and contribute to a poorer quality of
life [28,29] but there is much heterogeneity of reporting
behaviour and even some patients with severe airflow ob-
struction will not report exacerbations [30].
We observed that a significant falls in platelet count
occurred over the year proceeding patients changing
from the FE to IE group but the standard deviation of
these changes was too large to be of clinical utility.
Platelet count has been found to be elevated in COPD
compared to healthy controls [31] and increases during
lower respiratory tract infection [32]. Platelets are notonly involved in haemostasis but produce a broad array
of inflammatory mediators and factors that alter innate
and adaptive immunity [33,34]. We speculate that a
reduced platelet count is indicative of reduced airway
inflammation or improvement in immunity to infection
thus reducing susceptibility to future exacerbation. There
is also emerging evidence that statins, which reduce
platelet-activation [35], have the potential to reduce ex-
acerbation frequency in COPD [36].
The relatively large proportion of patients changing
from FE to IE could also be explained by the method by
which exacerbation frequency was assessed. A number
of patients could be experiencing three exacerbations
Table 3 Change in COPD patient characteristics between baseline and year 1 assessment
Year 1 Category Year 1 IE (n=1289) Year 1 FE (n=543)
Year 2 Category Stayed as IE (n=1068) Change to FE (n=221) p-value Stayed as FE (n=333) Change to IE (n=210) p-value
Change in patient measures (year 1 assessment – baseline)
BMI (kg/m2) 0.0 (1.4) 0.0 (1.1) 0.750 −0.1 (1.4) −0.1 (1.6) 0.589
FEV1 (mL) 14 (233) −46 (184) <0.001 −32 (180) −22 (217) 0.543
FEV1 % predicted 0.4 (7.7) −1.6 (6.9) <0.001 −1.1 (6.4) −0.9 (7.8) 0.690
FEV1/FVC % −0.1 (5.8) −0.4 (5.2) 0.534 −0.3 (6.0) −0.9 (6.0) 0.250
*Changed smoking status 6% 9% 0.053 6% 9% 0.153
*Re-Started smoking (%) 5% 9% 0.051 4% 4% 0.726
*Stopped smoking (%) 7% 10% 0.448 9% 17% 0.125
6-min walk distance (m) 10 (90) −5 (85) 0.036 −6 (94) −1 (84) 0.568
Blood oxygen saturation (%) 0.0 (2.9) −0.1 (3.0) 0.478 −0.3 (3.3) −0.2 (2.8) 0.713
mMRC Dyspnoea Score 0.0 (0.9) 0.0 (1.0) 0.682 0.1 (1.0) 0.0 (1.0) 0.691
SGRQ Total Score –2.0 (10.6) –1.9 (12.1) 0.879 −0.1 (9.9) −0.1 (10.2) 0.986
BODE Index 0.0 (1.2) 0.1 (1.3) 0.138 0.2 (1.5) 0.1 (1.3) 0.424
White blood cells (10^9/L) −0.3 (1.6) −0.2 (1.9) 0.606 0.0 (2.3) −0.2 (2.1) 0.289
Neutrophils (10^9/L) −0.2 (1.5) −0.2 (1.9) 0.894 0.2 (2.3) −0.1 (2.0) 0.232
Platelets (10^9/L) −7 (47) −11 (41) 0.238 −5 (51) −16 (49) 0.014
Fibrinogen (mg/dL) −6 [−51, 36] 0 [−38, 41] 0.151 5 [−41,58] −3 [−52, 38] 0.109
CRP (mg/dL) 0.1 [−1.3, 1.5] 0.0 [−1.8, 2.1] 0.999 0.3 [−1.4,3.0] −0.2 [−2.4, 1.9] 0.083
SP-D (ng/mL) 0 [−18, 20] 0 [−23, 26] 0.654 −1 [−24, 24] 0 [−21, 21] 0.806
PARC/CCL-18 (ng/mL) 6 [−6, 21] 6 [−9, 23] 0.628 9 [−6, 27] 6 [−7, 21] 0.114
Change between the number of events in year 1 and in year 2
PPPY COPD Hosp. Year 2 0.07 0.57 <0.001 0.68 0.14 <0.001
PPPY OCS only exbs Y2 0.04 0.25 <0.001 0.37 0.06 <0.001
P-values are comparisons between those who stayed in or changed exacerbation category. Mean (SD) or Median [25% - 75% percentile].
* - “Stopped smoking” are the current smokers at baseline who stopped before Year 1, “Re-started smoking” are the former smokers at baseline who started again
before Year 1.
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tions in year 1 and then one exacerbation in year 2. They
would initially be categorized as FE but change to IE in
the following year. Another possibility is that that patients
who normally experience two exacerbations per year
change to having 3 in one year and 1 in the next year, be-
cause they have an exacerbation just before, rather than
just after, the division between years. Another explanation
is that participation in an observational study reduces anx-
iety and/or improving adherence to treatment with a con-
sequential fall in exacerbation frequency.
There are a number of limitations concerning the major
findings that should be mentioned. A practice 6MWD test
was not performed and approximately 6% of the results
might have differed if this rehearsal had this been under-
taken [37]. The declines observed in FEV1 in the Eclipse
study [38] were modest but in-line with a recent interven-
tional study [39]. Measurements of FEV1 and blood cell
counts may have affected by exacerbations that took lon-
ger than 30 days to resolved, by the development of co-
morbidities or initiation of pulmonary rehabilitation. Theanalysis was based on change in the total number of exac-
erbations and we did not examine the data by change in
the number of hospitalized or oral corticosteroid treated
exacerbations.
Amongst the strengths of this study was the follow-up
of a large number of COPD patients with systematic mea-
surements on a wide variety of patient characteristics. The
patients were recruited worldwide from primary and sec-
ondary care and thus the results are generalizable to cli-
nical practice in COPD. We did not feel that changes in
oral or inhaled medication were responsible for a change
in exacerbation phenotype. Our reasons were the very
small proportion of patients involved and the impossibility
to determining whether any change in treatment was in
response to a rise in exacerbation frequency or to pre-
empt an increase.
Conclusion
Exacerbation frequency has been shown to be an import-
ant phenotype in COPD. A few patients may shift from
one category to another. There is no clear explanation or
Donaldson et al. Respiratory Research 2013, 14:79 Page 8 of 9
http://respiratory-research.com/content/14/1/79marker apart from the fact that patients on the borderline
between infrequent and frequent exacerbations are more
likely to change category. Thus, physicians need to con-
sider that all patients are at risk during the course of the
disease of becoming a frequent exacerbator.
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